Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well romidepsin works in treating patients with relapsed
or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as romidepsin, work in
different ways to stop tumor cells from dividing so they stop growing or die.